Pancreatic cancer: diagnosis and treatments

Tumor Biology

Volumn 36, Issue 3, 2015, Pages 1375-1384

  Li, Hong Yu ^a   Cui, Zhong Min ^a   Chen, Jiang ^a   Guo, Xiao Zhong ^a   Li, Ying Yi ^b  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Diagnosis; Pancreatic cancer; Treatment

Indexed keywords

TUMOR MARKER;

ANIMAL; HUMAN; METABOLISM; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; PROCEDURES; PROTEOMICS;

ANIMALS; COMBINED MODALITY THERAPY; HUMANS; PANCREATIC NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84930903894     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3223-7     Document Type: Review

References (75)

1. German RR, Fink AK, Heron M, Stewart SL, Johnson CJ, et al. The accuracy of cancer mortality statistics based on death certificates in the United States. Cancer Epidemiol. 2011;35:126–31.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
3. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–6.
4. Ariyama J, Suyama M, Satoh K, Sai J. Imaging of small pancreatic ductal adenocarcinoma. Pancreas. 1998;16:396–401.
5. Wasif N, Bentrem DJ, Farrell JJ, Ko CY, Hines OJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010;116:3369–77.
6. Kuvshinoff BW, Bryer MP. Treatment of resectable and locally advanced pancreatic cancer. Cancer Control. 2000;7:428–36.
7. Fusari M, Maurea S, Imbriaco M, Mollica C, Avitabile G, et al. Comparison between multislice CT and MR imaging in the diagnostic evaluation of patients with pancreatic masses. Radiol Med. 2010;115:453–66.
8. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson 3rd AB, et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010;8:972–1017.
9. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008;6:1301–8.
10. Philip A, Ramchandani S, Dorrance K, Dorrance C. Sildenafil-induced thrombocytopenia. Ann Intern Med. 2008;149:437–9.
11. Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, et al. Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg. 2004;187:736–40.
12. Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR. Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol. 2008;23:23–33.
13. Lee JG, Leung J. Tissue sampling at ERCP in suspected pancreatic cancer. Gastrointest Endosc Clin N Am. 1998;8:221–35.
14. Miyata H, Kuwahara K, Sugiyama S, Iiboshi T, Serikawa M, et al. A case of pancreatic solid-pseudopapillary tumor without cystic component in an elderly man. Nihon Shokakibyo Gakkai Zasshi. 2006;103:1288–95.
15. Hanninen EL, Ricke J, Amthauer H, Rottgen R, Bohmig M, et al. Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2- and T1-weighted sequences for the assessment of suspected pancreatic cancer. Acta Radiol. 2005;46:117–25.
16. Park HS, Lee JM, Choi HK, Hong SH, Han JK, et al. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging. 2009;30:586–95.
17. Ohtsuka T, Ideno N, Aso T, Nagayoshi Y, Kono H, et al. Role of endoscopic retrograde pancreatography for early detection of pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm of the pancreas. J Hepatobiliary Pancreat Sci. 2013;20:356–61.
18. Krishna NB, Mehra M, Reddy AV, Agarwal B. EUS/EUS-FNA for suspected pancreatic cancer: influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics. Gastrointest Endosc. 2009;70:70–9.
19. Hasan MK, Hawes RH. EUS-guided FNA of solid pancreas tumors. Gastrointest Endosc Clin N Am. 2012;22:155–67. vii.
20. Kedia P, Gaidhane M, Kahaleh M. Technical advances in endoscopic ultrasound (EUS)-guided tissue acquisition for pancreatic cancers: how can we get the best results with EUS-guided fine needle aspiration? Clin Endosc. 2013;46:552–62.
21. Chen J, Yang R, Lu Y, Xia Y, Zhou H. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for solid pancreatic lesion: a systematic review. J Cancer Res Clin Oncol. 2012;138:1433–41.
22. Salehimarzijarani B, Dadvar Z, Mousavi M, Mirsattari D, Zali MR, et al. Risk factors for post-ERCP cholangitis in patients with pancreatic cancer from a single referral center in Iran. Asian Pac J Cancer Prev. 2012;13:1539–41.
23. Dibble EH, Karantanis D, Mercier G, Peller PJ, Kachnic LA, et al. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol. 2012;199:952–67.
24. Strobel O, Buchler MW. Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol Hepatol. 2013;10:203–5.
25. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson 3rd AB, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012;10:703–13.
26. Luo G, Xiao Z, Long J, Liu Z, Liu L, et al. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg. 2013;17:2092–8.
27. van den Bosch RP, van Eijck CH, Mulder PG, Jeekel J. Serum CA19-9 determination in the management of pancreatic cancer. Hepatogastroenterology. 1996;43:710–3.
28. Gui JC, Yan WL, Liu XD. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med. 2014;14:225–33.
29. Rothlin MA, Joller H, Largiader F. CA 242 is a new tumor marker for pancreatic cancer. Cancer. 1993;71:701–7.
30. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160:1239–49.
31. Li JJ, Li HY, Gu F. Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis. Genet Test Mol Biomarkers. 2014;18:580–6.
32. Bunger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137:375–89.
33. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.
34. Kondo H, Sugano K, Fukayama N, Hosokawa K, Ohkura H, et al. Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer. 1997;79:900–5.
35. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–48.
36. Zhang J, Wang M, He S, Liu Y, Zhang B. The growth inhibitory effects by transfection of p16 gene on human pancreatic cancer cell line. Zhonghua Wai Ke Za Zhi. 2000;38:457–9.
37. Zhang L, Gao J, Li L, Li Z, Du Y, et al. The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. Mol Biol Rep. 2011;38:4903–11.
38. Sato N, Mizumoto K, Nagai E, Tanaka M. Telomerase as a new target for pancreatic cancer treatment. J Hepatobiliary Pancreat Surg. 2002;9:322–7.
39. Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 2004;64:5504–10.
40. Guo J, Wang W, Liao P, Lou W, Ji Y, et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 2009;100:2292–301.
41. Qian JY, Mou SH, Liu CB. SELDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of a boosting decision tree model for diagnosis of pancreatic cancer. Asian Pac J Cancer Prev. 2012;13:1911–5.
42. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.
43. Kawarada Y, Yokoi H, Isaji S, Naganuma T, Tabata M, et al. Modified standard pancreaticoduodenectomy for the treatment of pancreatic head cancer. Digestion. 1999;60 Suppl 1:120–5.
44. Malleo G, Marchegiani G, Salvia R, Butturini G, Pederzoli P, et al. Pancreaticoduodenectomy for pancreatic cancer: the Verona experience. Surg Today. 2011;41:463–70.
45. Evans DB, Farnell MB, Lillemoe KD, Vollmer Jr C, Strasberg SM, et al. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1736–44.
46. Takahashi H, Ohigashi H, Ishikawa O. Pancreaticoduodenectomy for invasive pancreatic cancer (with video). J Hepatobiliary Pancreat Sci. 2012;19:100–8.
47. Srinarmwong C, Luechakiettisak P, Prasitvilai W. Standard whipple’s operation versus pylorus preserving pancreaticoduodenectomy: a randomized controlled trial study. J Med Assoc Thai. 2008;91:693–8.
48. Takahashi Y, Kaneoka Y, Maeda A, Isogai M. Distal pancreatectomy with celiac axis resection for carcinoma of the body and tail of the pancreas. World J Surg. 2011;35:2535–42.
49. Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg. 2007;204:244–9.
50. Casadei R, Monari F, Buscemi S, Laterza M, Ricci C, et al. Total pancreatectomy: indications, operative technique, and results: a single centre experience and review of literature. Updates Surg. 2010;62:41–6.
51. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–8.
52. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
53. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.
54. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402–8.
55. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–16.
56. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–52.
57. Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial—SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008;26:3695–701.
58. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2007;25:1960–6.
59. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008;113:2046–52.
60. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007;25:4787–92.
61. Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, et al. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer. 2000;89:303–13.
62. Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14:1095–103.
63. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000;89:314–27.
64. Assifi MM, Lu X, Eibl G, Reber HA, Li G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466–73.
65. Spry N, Harvey J, Macleod C, Borg M, Ngan SY, et al. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. Int J Radiat Oncol Biol Phys. 2008;70:1438–46.
66. Wu W, Zhu F, Chang D, Wang J, Wang Y. Dosimetric comparison of treatment plans of pancreatic carcinoma treated with body gamma knife and tomotherapy. Zhongguo Yi Liao Qi Xie Za Zhi. 2013;37:232–4.
67. Guo XZ, Cui ZM, Liu X. Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. World J Gastrointest Oncol. 2013;5:20–8.
68. Du Y, Jin Z, Meng H, Zou D, Chen J, et al. Long-term effect of gemcitabine-combined endoscopic ultrasonography-guided brachytherapy in pancreatic cancer. J Interv Gastroenterol. 2013;3:18–24.
69. Wang K, Chen Z, Meng Z, Lin J, Zhou Z, et al. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia. 2011;27:101–7.
70. Xie Q, Jia L, Liu YH, Wei CG. Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World J Gastroenterol. 2009;15:737–41.
71. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37 Suppl 4:S9–15.
72. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 2012;30:1138–43.
73. Zhang Z, Wang J, Shen B, Peng C, Zheng M. The ABCC4 gene is a promising target for pancreatic cancer therapy. Gene. 2012;491:194–9.
74. Engelhardt K, Riley C, Cooke L, Mahadevan D. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma. Curr Drug Discov Technol. 2006;3:231–43.
75. Takeda Y, Nakahira S, Katsura Y, Kagawa Y, Okishiro M, et al. Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer—a single-institution experience. Gan To Kagaku Ryoho. 2013;40:1884–6.